Safety and efficacy of abemaciclib plus endocrine therapy in older patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: an age-specific subgroup analysis of MONARCH 2 and 3 trials

Matthew P. Goetz, Meena Okera, Hans Wildiers, Mario Campone, Eva-Maria Grischke, Luis Manso, Valérie A. M. André, Nadia Chouaki, Belén San Antonio, Masakazu Toi, George W. Sledge

Open source

DOI: 10.1007/s10549-020-06029-y
Published: 2021-01-03
Container: Breast Cancer Research and Treatment
Publisher: Springer Science and Business Media LLC
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1007/s10549-020-06029-y,
  title = {Safety and efficacy of abemaciclib plus endocrine therapy in older patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: an age-specific subgroup analysis of MONARCH 2 and 3 trials},
  author = {Matthew P. Goetz and Meena Okera and Hans Wildiers and Mario Campone and Eva-Maria Grischke and Luis Manso and Valérie A. M. André and Nadia Chouaki and Belén San Antonio and Masakazu Toi and George W. Sledge},
  year = {2021},
  journal = {Breast Cancer Research and Treatment},
  doi = {10.1007/s10549-020-06029-y},
  url = {https://doi.org/10.1007/s10549-020-06029-y}
}

RIS

TY  - JOUR
TI  - Safety and efficacy of abemaciclib plus endocrine therapy in older patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: an age-specific subgroup analysis of MONARCH 2 and 3 trials
AU  - Matthew P. Goetz
AU  - Meena Okera
AU  - Hans Wildiers
AU  - Mario Campone
AU  - Eva-Maria Grischke
AU  - Luis Manso
AU  - Valérie A. M. André
AU  - Nadia Chouaki
AU  - Belén San Antonio
AU  - Masakazu Toi
AU  - George W. Sledge
PY  - 2021
JO  - Breast Cancer Research and Treatment
DO  - 10.1007/s10549-020-06029-y
UR  - https://doi.org/10.1007/s10549-020-06029-y
ER  -

APA

Goetz, M. P., Okera, M., Wildiers, H., Campone, M., Grischke, E., Manso, L., André, V. A. M., Chouaki, N., Antonio, B. S., Toi, M., & Sledge, G. W. (2021). Safety and efficacy of abemaciclib plus endocrine therapy in older patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: an age-specific subgroup analysis of MONARCH 2 and 3 trials. Breast Cancer Research and Treatment. https://doi.org/10.1007/s10549-020-06029-y

Source records

crossref · retrieved 2026-09-26T19:17:52.109Z